Estimating the Economic Burden of Typhoid Fever in Ibadan, Nigeria

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background

Evidence on the economic burden of typhoid fever remains limited in sub-Saharan Africa. This study estimated the costs associated with typhoid fever and related invasive Salmonella infections in Ibadan, Nigeria.

Methods

A field-based cost-of-illness study was conducted at six healthcare facilities between 2022 and 2025. Patients with Salmonella enterica serovar Typhi ( S . Typhi), Salmonella enterica serovar Paratyphi ( S . Paratyphi), invasive non-typhoidal Salmonella (iNTS), or typhoid gastrointestinal perforation (special cases) were enrolled, with malaria patients serving as controls. Direct medical, direct non-medical, and indirect costs were estimated for each episode and converted from Nigerian naira to US dollars using year-specific exchange rates for 2022–2025. Cases and controls were matched by age group, sex, and point of care, and confidence intervals were estimated using non-parametric bootstrapping.

Results

Among 198 participants, 69 were S . Typhi cases, one was S . Paratyphi case, 14 were iNTS cases, 12 were special cases, and 102 were malaria controls. Average total costs per episode were $130 for S . Typhi, $27 for S . Paratyphi, $156 for iNTS, $583 for special (perforation) cases, and $52 for malaria. For S . Typhi, costs were substantially higher among inpatients than outpatients ($309 vs. $72). Compared with matched malaria controls, the mean incremental total costs were $42 (95% CI: 18–71) for S . Typhi, $104 (95% CI: 25–197) for iNTS, and $560 (95% CI: 289–882) for special (perforation) cases.

Conclusions

Typhoid fever imposes a considerable economic burden in Ibadan, Nigeria, particularly among patients requiring hospitalization or experiencing severe complications. These findings provide locally relevant evidence for evaluating typhoid conjugate vaccine introduction and informing resource-allocation decisions.

Article activity feed